Press Releases :: BiomX, Inc. (PHGE)

Nov 30, 2023 4:15pm EST

BiomX to Host Virtual Key Opinion Leader (KOL) Event to Review the Positive Results from Part 2 of Phase 1b/2a Trial of BX004 in Cystic Fibrosis Patients with Chronic Pseudomonas aeruginosa Infections on December 4, 2023

Nov 29, 2023 6:30am EST

BiomX Announces Positive Topline Results from Part 2 of the Phase 1b/2a Trial Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis

Nov 14, 2023 6:30am EST

BiomX Reports Third Quarter 2023 Financial Results and Provides Business Update

Oct 27, 2023 8:00am EDT

BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the 37th Annual North American Cystic Fibrosis Conference

Oct 18, 2023 8:00am EDT

BiomX Announces the Appointment of Edward L. Williams to its Board of Directors

Oct 04, 2023 6:34am EDT

BiomX Announces Completion of Patient Dosing in Part 2 of the Phase 1b/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis

Sep 07, 2023 9:00am EDT

BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the European Respiratory Society (ERS) International Congress 2023

Sep 06, 2023 4:05pm EDT

BiomX to Present at H.C. Wainwright 25th Annual Global Investment Conference

Aug 09, 2023 6:30am EDT

BiomX Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 02, 2023 4:30pm EDT

BiomX to Host Second Quarter 2023 Financial Results Conference Call and Webcast on August 9th, 2023

1
2
3
4
5
6
7
8
9
10
Next

Investor Contact Information

Company

BiomX, Inc.
22 Einstein St.
Floor 5
Ness Ziona 7414003
Israel
info@biomx.com

Investor Relations

Anat Primovich
Corporate Project Manager
T: +972506977228
anatp@biomx.com